Panretin: profile and news

Ligand Announces Financial Results for First Quarter of Fiscal ... May 15, 2006
...this release. AVINZA, Targretin, ONTAK and Panretin are registered trademarks of Ligand Pharmaceuticals Incorporated. Each other ... - Genetic Engineering News,

Other information

Indication
For topical treatment of cutaneous lesions in patients with AIDS- related Kaposi sarcomaia.

Pharmacology
Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS- related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro.

Mechanism Of Action
Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells.

Drug Category
Antineoplastic Agents; ATC:L01XX22

Brand Names/Synonyms
Alitretinoin; Alitretinoin [Usan]; Avita; Beta-Retinoic Acid; Panretin; Panretin Gel; Panretyn; Panrexin; Renova; Retin-A; Retin-a Micro; Retinoate; Retinoic Acid; Trans-Retinoic Acid; Tretin M; Tretinoin; Vesanoid; Vitamin a Acid

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Interactions for Alitretinoin:

Patients who are applying Panretin® gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products. Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation. Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin® gel on the steady-state concentrations of these drugs is not known. No drug interaction data are available on concomitant administration of Panretin® gel and systemic anti-KS agents.

Chemical IUPAC Name
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-nona-2,4,6,8-tetraenoicacid

Chemical Formula
C20H28O2

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
APRD00017

CAS Registry Number
3/8/5300